CD101 is a nanoparticulate formulation that slowly releases paclitaxel in a controlled fashion. Its main features are:
- Application in therapeutic areas including breast, lung and ovarian tumours
- Concentration up to at least 10 mg/mL paclitaxel
- No acute dose dumping upon intravenous administration, in contrast to Taxol® or other nanoparticulate-based paclitaxel formulations.
- Enhanced safety profile compared to currently marketed products, allowing higher dosages
- Increased accumulation at target site
- Sustained drug blood levels (see Figure), requiring less administrations
- Pharmacokinetic blood profile of CD101 upon intravenous administration of 10 mg/kg paclitaxel to healthy C57Bl6 mice: released free and total paclitaxel in time. For comparison: the commercial formulation Taxol is rapidly cleared, and blood levels are below the limit of detection after 2.5 hours in mice.
Current formulations of paclitaxel are highly effective anticancer drugs, but clinical practice reveals high incidences of adverse reactions. These dictate limitations to the dose strength, thus preventing optimal treatment. The unique profile of CD101 is designed to generate a superior risk-benefit ratio, positioning it to be best-in-class of paclitaxel-treatments. CD101 is currently in late stages of preclinical development and has shown favourable PK/PD and safety profiles.
For prospective licensing partners, an extensive data package is available. Please use our contact page to request more information.